|
Indian Pharma Market registers 51.5% growth in April 2021
|
|
Yash Ved, Mumbai
May 19 , 2021
|
|
|
The Indian Pharmaceutical Market (IPM) has registered a growth of 51.5 per cent for the month of April 2021, as against a growth of 10.3per cent for the month of March 2021.
According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,52,826 crore for moving annual total (MAT) basis during April 2021.
Amongst the top 10 corporates, Cipla exhibited the highest growth of 13.6 per cent, followed by Intas at 8.2 per cent. Amongst the 11 to 25 ranked corporates, Glenmark exhibited highest growth of 29.2 per cent followed by Himalaya at 18.5 per cent.
Amongst the 26 to 50 ranked corporates, Apex registered the highest growth 40 per cent followed by Bharat Serums at 17 per cent. Amongst the 51 to 75 ranked corporates, Danone registered the highest growth 33.3 per cent and Alniche Life Science at 29.3 per cent.
Amongst the 76 to 100 ranked corporates, Fusion healthcare exhibited the highest growth at 62.8 per cent, followed by Charak at 18.3 per cent.
“Pharma industry has been well prepared for production and distribution exigencies that are expected during lockdown,” AIOCD-AWACS report stated.
The report said, “Covid second wave has further boosted the sales of drugs having direct/indirect role in treatment. Anti-infectives have shown a growth of 134 per cent and nutritionals have shown a growth of 76 per cent.”
Companies operating in Covid treatment therapy segments have gained substantially through bumper sales for the month. Substantial changes in brand and company ranking seen this month, the report said.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|